Gilead's Descovy nabs PrEP nod. Next step: Convert Truvada patients before generics hit

4th October 2019 Uncategorised 0

As expected, the FDA has approved the second HIV PrEP drug in Gilead Sciences’ Descovy—excluding cisgender women. Now it’s up to the Big Biotech to convince as many current Truvada takers to switch over before generics to the older med hit in a year.

More: Gilead's Descovy nabs PrEP nod. Next step: Convert Truvada patients before generics hit
Source: fierce